Table 1 Patient characteristics
Characteristics | (n = 1394) |
|---|---|
Prior COVID-19, n (%) | 109 (7.9) |
Diagnosed by PCR | 95 (7) |
Positive serostatus prior to vaccination | 37 (2.6) |
Negative serostatus prior to vaccination | 13 (1) |
Detected by pre-vaccine serological test | 14 (1.5) |
Median time from COVID-19 to vaccination, days (range) | 185 (33–460) |
Serological status prior to vaccination, n (%) | |
Positive | 50 (4) |
Negative | 422 (30) |
Not tested | 922 (66) |
Median time from serology to vaccination, days (range) | 0 (0–386) |
Type of vaccine, n (%) | |
Moderna mRNA-1273 | 983 (70.5) |
Pfizer-BioNTech BNT162b2 | 362 (26) |
Adenoviral vector-based | 49 (3.5) |
Age (years), median (range) | 63 (18–97) |
18–40 years, n (%) | 143 (10) |
41–60 years, n (%) | 496 (35.5) |
61–70 years, n (%) | 373 (26.8) |
> 71 years, n (%) | 382 (27.4) |
Male, n (%) | 784 (56.3) |
ECOG 0–1 at vaccination | 1351 (97) |
Baseline disease, n (%) | |
AML | 179 (12.8) |
ALL | 46 (3.3) |
MDS | 158 (11.3) |
B-cell NHL | 302 (21.6) |
T cell NHL | 38 (2.7) |
Plasma cell disorders | 236 (16.9) |
CLL | 158 (11.3) |
HD | 103 (7.4) |
cMPN | 139 (10) |
Aplastic anemia | 16 (1) |
Non-malignant disorders | 18 (1.3) |
Type of cell therapy | |
Allo-HSCT | 369 (26.5) |
ASCT | 110 (8) |
CAR-T | 21 (1.5) |
Status disease at vaccination, n (%) | |
Complete remission | 824 (59.2) |
Partial remission | 162 (11.6) |
Active disease | 408 (29.2) |
Time last treatment to COVID-19 vaccine, months (range) | |
Untreated | 172 (12.3) |
Active treatment | 509 (36.5) |
≥ 6 month to 1 year | 92 (6.6) |
≥ 1 year | 621 (44.5) |
Immunosuppressant drugs at vaccination, n (%) | 300 (21.5) |
Corticosteroids at vaccination, n (%) | 255 (18.6) |
Daratumumab, n (%) | 46 (3.3) |
Venetoclax, n (%) | 14 (1) |
Anti-CD-20 moAb, n (%) | 241 (17.3) |
< 6 months before 1st vaccine dose | 87 (6.2) |
6 to 1 year before 1st vaccine dose | 25 (1.8) |
> 1 year before 1st vaccine dose | 129 (9.3) |
BTK inhibitor therapy, n (%) | 63 (4.5) |
TKI therapy, n (%) | 40 (2.9) |
Lenalidomide maintenance, n (%) | 120 (8.6) |
Ruxolitinib therapy, n (%) | 14 (1) |
Blood count before vaccination (× 109/mL) | |
Absolute neutrophile counts, median (range) | 3.1 (0–46.7) |
Absolute lymphocyte counts, median (range) | 1.73 (0.14–262.1) |
Absolute lymphocyte counts < 1 × 109/L | 265 (18.6) |
Time from 2nd dose to first serologies, median days (range) | 21 (12–62) |
Median time between vaccine doses, median days (range) | 28 (17–115) |
SCoV2-R-A detection at 3–6 weeks after full vaccination, n (%) | 1090 (78.2) |
Patient with SCoV2-R-A titers at 3–6 weeks in BAU/mL, n (%) | 1244 (89%) |
Median SCoV2-R-A titers at 3–6 weeks in BAU/mL, (range) | 715 (0–56,800) |
Third vaccine dose given, n (%) | 550 (39.5) |
Time from 2nd dose to 3rd dose, days (range) | 153 (39–269) |
Median follow-up after full vaccination, days (range) | 165 (12–269) |
COVID-19 after vaccination, n (%) | 37 (2.7) |
Median time from vaccination to SARS-CoV-2 infection, days (range) | 77 (7–195) |